The Pharmacy Times® Lung Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that begins on the lungs, including non-small cell lung cancer and small cell lung cancer.
May 7th 2024
Pharmacists can raise awareness for lung cancer during and after Lung Cancer Action Week.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Mastering Oncology Clinical Trials: Immune Checkpoint Inhibitors in Frontline Metastatic Non–Small Cell Lung Cancer
1.5 Credits / Lung Cancer, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Pharmacists in the Oncology Setting: Financial and Clinical Impact is Significant
November 3rd 2022In the inpatient acute care setting, oncology pharmacists maximize return on investments of oncology products, produce optimal outcomes, and ensure that quality of care is consistent and safe.
Read More
Dostarlimab Plus Chemotherapy Shows Promise in Non-Small Cell Lung Cancer
October 6th 2022Results from the largest head-to-head trial of programmed death receptor-1 inhibitors suggest that dostarlimab and chemotherapy could be an effective treatment option for patients with metastatic non-squamous non-small cell lung cancer.
Read More
FDA Approves Bevacizumab Biosimilar for Six Types of Cancer
September 28th 2022Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
Trastuzumab Deruxtecan Shows Clinically Meaningful Response in Non-Small Cell Lung Cancer
September 13th 2022Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.
Read More
Phase 3 Trial Investigating Onivyde for Small Cell Lung Cancer Fails to Meet Primary End Point
August 23rd 2022Irinotecan liposomal injection (Onivyde) used as second-line therapy for patients with small cell lung cancer did not meet the primary end point of overall survival compared to topotecan.
Read More